Additionally, we found LSD1 was positively correlated with the degree of malignancy of hepatocellular carcinoma, as evidenced by higher expression levels of LSD1 in late-stage liver cancer compared with other stages (here, samples of stage IV had been excluded due to the small sample size), indicating LSD1 might contribute to the de novo resistance of Lenvatinib in patients with late-stage liver cancer (Additional file 1: Figure S1). Here, KDM1A is linked to hepatocellular carcinoma.